On December 13, the National Health Insurance Administration released the latest 2024 version of the National Medical Insurance Catalogue, in which 21 new anti-cancer drugs entered the medical insurance for the first time, and another 15 anti-cancer drugs expanded the scope of medical insurance reimbursement.
There is no doubt that non-small cell lung cancer is the cancer with the most medical insurance drugs, and in the 2024 version of the medical insurance catalog, there are a total of 23 ** drugs for non-small cell lung cancer:
Icotinib, dacotinib, osimertinib, ametinib, fumetinib,Befatinib, anlotinib, crizotinib, ceritinib, alectinib, ensartinib, lorlatinib, brigatinib,IruAke, savolitinib,GlutatinibEntrectinib, trametinib, dabrafenib, sintilimab, tislelizumab,Toripalimab, camrelizumab.
A new drug entered the medical insurance for the first time
Among the 23 lung cancer medical insurance drugs, 4 drugs are new drugs and have entered the medical insurance list for the first time. They are:
Befatinib mesylate capsules:
Patients with locally advanced or transmobile non-small cell lung cancer (NSCLC)** who have progressed on or after prior transepidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)** and who have been tested to be positive for EGFR T790M mutations.
Entrectinib capsules:
1) Solid tumors 12 years of age and older, diagnosed with neurotrophic tyrosine receptor kinase (NTRK) fusion genes and excluding known acquired drug resistance mutations: patients with locally advanced, metastatic disease or surgical resection that may lead to serious complications, or patients with no satisfactory replacement **or previous** failure;
2) ROS1-positive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)**.
Glutalitenib tablets:
Locally advanced or metastatic non-small cell lung cancer with mesenchymal-epithelial transition factor (met) exon 14 skipping alterations.
Iruaq Tablets:
Locally advanced or metastatic disease progression after prior treatment with crizotinib ** or anaplastic lymphoma kinase (ALK)-positive intolerance to crizotinib.
Expand the scope of reimbursement for individual drugs
There are 3 lung cancer drugs that have expanded the scope of medical insurance reimbursement, among which toripalimab is the first time that non-small cell lung cancer has been included in medical insurance.
Toripalimab
First-line treatment of epidermal growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma kinase (ALK)-negative, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)**.
Sintilimab:
1) First-line treatment of epidermal growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma kinase (ALK)-negative, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)**;
2) Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)** EGFR gene mutation-positive patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)**.
Osimertinib mesylate tablets:
Patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutations** who have undergone prior surgical resection** and receive adjuvant chemotherapy at the discretion of the physician.
Other lung cancer medical insurance drugs
The other 16 lung cancer drugs have been included in the medical insurance before, and this time they will continue to stay in the medical insurance list. Includes:
Icotinib, dacotinib, ametinib, fumetinib, anlotinib, crizotinib, ceritinib, alectinib, ensartinib, lorlatinib, brigatinib, savolitinib, trametinib, dabrafenib, tislelizumab, camrelizumab. List of high-quality authors